跳至主要内容
临床试验/NL-OMON46054
NL-OMON46054已完成不适用

A Multi-cohort, Randomized Study in Healthy Subjects to Assess the Pharmacokinetics and Safety of Single and Multiple Ascending Doses of JNJ-61393215 (Suspension), and to Assess the Relative Bioavailability, and the Effect of Food on the Pharmacokinetics, of a New Solid Formulation (Capsules) of JNJ-61393215 - Orexin SAD MAD FE BA

Janssen-Cilag International NV0 个研究点目标入组 56 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
56

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -Healthy male or female subjects
  • -18-55 yrs, inclusive at screening
  • -BMI: 18.0-30.0 kg/m2, inclusive at screening
  • -Weight not less than 50 kg at screening
  • -Non-smoking
  • -Female of non-childbearing potential
  • -Blood pressure between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic.

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

相似试验